fsdpharma.com (HUGE): Total Asset Value of Company

This price visualization, which assists in the basic asset valuation, shows the total assets of FSD Pharma Inc. (HUGE) at 22.47. The Canadian enterprise focuses on creating innovative therapies for CNS disorders. Operations are complicated by significant R&D costs and the uncertainty of FDA verdicts. Meanwhile, its pre-commercial status allows the company to avoid price wars, although the competition for funding among small biotech startups remains extremely fierce.

FSD Pharma Inc. (HUGE) Company Total Assets: for the period 07/04/2022 - 08/15/2024

Comprehensive metric breakdowns and analytics for FSD Pharma Inc. (HUGE)

- price and consensus price forecast:

Market Price FSD Pharma, Inc.|HUGE - Price Target Chart

- market capitalization data:

Market Valuation FSD Pharma Inc.|HUGE - Enterprise Value

- book capitalization data:

Accounting Value of a Share FSD Pharma|HUGE - Book Capitalization|Market Capitalization to Book Value Ratio fsdpharma.com|HUGE - Aggregate Company Assets

- debt and liquidity data:

All Debt to Shareholders' Equity Ratio FSD Pharma Inc.|HUGE - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio fsdpharma.com|HUGE - Company Aggregate Debts|Debts to Book Capitalization FSD Pharma Inc.|HUGE - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings FSD Pharma

Fundamental valuation:HUGE, FSD Pharma, Inc.

This metric represents a reverse calculation of total resources via return on assets (ROA), allowing for an assessment of capital management efficiency relative to the WACC hurdle rate. For FSD Pharma Inc. (HUGE), the dynamics of this parameter reflect the capitalization of intellectual property and material bases established through biopharmaceutical alliances, rendering asset and resource growth an indicator of scaling clinical research potential.

Competitors of FSD Pharma Inc. (HUGE)

JAZZ (jazzpharma.com) - Company Assets|Aggregate Company Assets Cytokinetics, Incorporated CYTK|Total Asset Value of Company PTC Therapeutics Inc|Scholar Rock Corp (SRRK) - Company Total Assets|Aggregate Asset Value Centessa Corp (CNTA)|Company Total Assets DYN (Dyne Therapeutics, Inc.)|edgewisetx.com - Company Total Assets|Aggregate Company Assets Rapport Therapeutics (RAPP)|ALMS: Aggregate Asset Value|ZVRA (Kempharm) - Aggregate Company Assets|Contineum Corp (CTNM) - Cumulative Company Assets|LRMR (Larimar Therapeutics) - Company Total Assets|Company Total Assets Capricor (CAPR)|Entrada Therapeutics, Inc. (TRDA) - Cumulative Company Assets|Aggregate Asset Value PTHS (Channel Therapeutics Inc.)|MNOV - Aggregate Company Assets|Total Business Assets Serina Pharma SER|BTAI (BioXcel Therapeutics) - Company Total Assets|ProMIS Neurosciences (PMN) - Company Assets|APUS: Cumulative Company Assets|AEON (AEON Biopharma, Inc.) - Company Total Assets|NLSP - Aggregate Company Assets|Aggregate Asset Value BNOX|Reata Pharmaceuticals - Aggregate Company Assets